Chemours (CC) Projected to Post Earnings on Thursday

Chemours (NYSE:CC) is expected to release its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Chemours to post earnings of $0.32 per share and revenue of $1.4994 billion for the quarter. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, November 7, 2025 at 8:00 AM ET.

Chemours (NYSE:CC) last released its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The firm had revenue of $1.62 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the prior year, the company earned $0.38 earnings per share. The company’s quarterly revenue was up 5.0% on a year-over-year basis. On average, analysts expect Chemours to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Chemours Trading Down 0.8%

NYSE CC opened at $13.74 on Thursday. The company has a quick ratio of 0.83, a current ratio of 1.68 and a debt-to-equity ratio of 17.16. Chemours has a twelve month low of $9.13 and a twelve month high of $22.38. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -4.91 and a beta of 1.65. The business’s fifty day moving average is $15.24 and its 200 day moving average is $13.18.

Chemours Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 15th were issued a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Friday, August 15th. Chemours’s payout ratio is presently -12.50%.

Insider Buying and Selling

In other Chemours news, CEO Denise Dignam purchased 4,068 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the transaction, the chief executive officer directly owned 191,546 shares in the company, valued at approximately $2,310,044.76. The trade was a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.47% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CC. B. Riley Wealth Advisors Inc. bought a new position in shares of Chemours in the 2nd quarter worth $116,000. Oxford Asset Management LLP bought a new position in shares of Chemours in the 2nd quarter worth $124,000. Baird Financial Group Inc. bought a new position in shares of Chemours in the 1st quarter worth $148,000. AQR Capital Management LLC bought a new position in shares of Chemours in the 1st quarter worth $161,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Chemours by 18.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,123 shares of the specialty chemicals company’s stock worth $139,000 after purchasing an additional 1,925 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CC. Truist Financial raised their target price on Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Zacks Research lowered Chemours from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. UBS Group raised their target price on Chemours from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, October 6th. Royal Bank Of Canada set a $19.00 target price on Chemours and gave the stock an “outperform” rating in a research report on Tuesday, October 14th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $18.50.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.